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Introduction
Chemokines (chemotactic cytokines) are small
heparin-binding proteins that direct the migration of
circulating leukocytes to sites of inflammation or
injury [1-3]. The largest family is known as the CC
chemokines, because of the fist two of the four con-
served cysteine residues, and the most thoroughly
characterized CC chemokine is MCP-1 (monocyte
chemoattractant protein 1), also known as CCL2 - a
potent agonist for monocytes, memory T cells and
basophils [1]. MCP-1 has been implicated as a key
player in the recruitment of monocytes from the blood
into early atherosclerotic lesions, the development of
intimal hyperplasia after angioplasty, as well as in vas-
culogenesis and thrombosis [1]. MCP-1 is also
expressed and secreted by adipocytes and has been
reported to be involved in the recruitment and activa-
tion of peripheral blood leukocytes in adipose tissue
and in the induction of systemic insulin resistance [4-
6]. Recently Zhou et al. [7] reported the identification
of a novel protein, designated MCPIP (MCP-induced
protein), which is expressed in human monocytes and
cardiomyocytes after stimulation with MCP-1. Their
results provided a novel molecular pathway, by which
MCP-1 signal transduction is linked to transcriptional
gene regulation leading to apoptosis [7].
Elevated levels of circulating MCP-1 have been
found in patients with type 1 and type 2 diabetes [8-
14], hypercholesterolemia [15], arterial hypertension
[16], congestive heart failure [17] and coronary artery
disease [18-20]. In vitro studies demonstrated that
advanced glycation end-products, high glucose con-
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current BMI (r=0.3501, p=0.0057 and r=0.3250, p=0.0106, respectively). Multiple regression analysis revealed that MCP-
1 concentrations were significantly predicted only by plasma glucose (β=0.3489, p=0.00004). Our results suggest that MCP-
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centration, glycated albumin and glycoxidized LDL
enhanced MCP-1 expression in human endothelial
cells [21].
Gestational diabetes mellitus (GDM), defined as a
carbohydrate intolerance of varying severity, with onset
or first recognition during pregnancy [22], is considered
a prediabetic state or a transient unmasking of the meta-
bolic syndrome, offering a unique opportunity to study
abnormalities that may appear very early in the devel-
opment of type 2 diabetes [23]. Di Benedetto et al. [24]
demonstrated that women with and without a history of
GDM had comparable serum levels of MCP-1, but to
our best knowledge there are no reports regarding MCP-
1 concentrations during pregnancy complicated by
GDM. So, in the present study we evaluated MCP-1
serum levels in pregnant women with normal glucose
tolerance (NGT) and GDM and established their rela-
tion to a range of anthropometric and metabolic factors
conferring insulin resistance.
Materials and methods
Patients. The studied group consisted of 62 patients with GDM
and 64 pregnant women with NGT, attending the gynaecological
out - patient clinic of the Medical University of Bialystok: The
control group consisted of 34 non-pregnant healthy women, eight
of whom had one or more pregnancies without a history of GDM
and 26 had no previous pregnancy. All subjects were non-smokers
and had not taken any anti-inflammatory drugs or drugs known to
affect carbohydrate metabolism in the previous 3 months. Patients
with pregnancy induced hypertension (PIH), preeclampsia and
other pregnancy complications (except GDM) were not included.
All pregnancies were singletons. The estimation of pregnancy
duration was based on routine ultrasonographic examination pre-
formed between 10 and 12 weeks of gestation. GDM was diag-
nosed according to the Polish Diabetological Association criteria
(fasting plasma glucose  100 mg/dl [5.55 mmol/L] or/and plasma
glucose 2-h after 75g glucose load  140 mg/dl [7.8 mmol/L]). Writ-
ten informed consent was obtained from all participants, and the
protocol was approved by the local ethics committee (Medical
University of Bialystok). 
For each patient body mass index (BMI) was calculated at the
time of blood collection as weight in kilograms divided by height
in meters squared. Medical records were also revised to collect
information concerning subject's weight shortly before conception,
and prepregnancy BMI was calculated as described above. Fasting
plasma glucose concentration was measured using oxidase method
(CORMAY, Poland) and fasting serum insulin level was assayed
by immunoradiometric method (Biosource Europe SA, Belgium).
MCP-1 serum concentration was measured using human ultrasen-
sitive ELISA kit (Bender MedSystems GmbH, Austria) with the
detection limit of less than 2.31 pg/ml. The intraassay and interas-
say coefficients of variation (CVs) were less than 4.7% and 8.7%,
respectively. 
Insulin resistance. Insulin resistance was estimated by HOMA
(Homeostasis Model Assessment) (25) and QUICKI (Quantitative
Insulin Sensitivity Check Index) (26). An insulin resistance score
(HOMA-IR) was computed with the formula: fasting plasma glu-
cose (mmol/l) times fasting serum insulin (mU/l) divided by 22.5
(25). Insulin sensitivity index (ISQUICKI) was calculated as the
inverse log sum of fasting insulin (I0 [mU/l]) and fasting glucose
(G0 [mg/dl]): ISQUICKI=1/[log(I0) + log(G0)] (26).
Statistical analysis. Statistical analysis was performed using the
STATISTICA 7.0 for Windows software package (StatSoft.Inc,
Tulsa, USA). The variables the distribution of which was substan-
tially skewed, were expressed as medians and interquartile ranges
(IR). Other results were showed as means ± SD. The differences
between the groups were compared by Mann - Whitney U test.
Multiple least - square regression procedure was used to estimate
mean case - control differences in serum MCP-1 concentration
after adjusting for potential confounders. Relationships between
variables were tested by Spearman's rank correlations. Moreover,
multivariate linear regression analysis was performed to establish
which factors were significantly and independently associated with
the variance in MCP-1 serum concentration. p value less than 0.05
was regarded as statistically significant. 
Results
Clinical and biochemical characteristics of the groups
studied are summarized in Table 1. Patients with
GDM were significantly more obese before pregnan-
cy, had higher fasting insulin levels and HOMA-IR
and lower ISQUICKI values than the control group, as
well as significantly higher plasma glucose, HOMA-
IR and lower ISQUICKI than the pregnant women with
NGT. The subjects with NGT had markedly lower
fasting glucose and higher insulin levels in compari-
son with the non-pregnant women. MCP-1 concen-
trations were comparable in the NGT and GDM
groups, but significantly lower than in the non-preg-
nant group (Table 1).
In a pooled analysis MCP-1 correlated significant-
ly with fasting glucose (r=0.3330, p<0.0001), HOMA-
IR (r=0.1726, p=0.0296) and ISQUICKI (r=-0.1726,
p=0.0296). In the GDM group MCP-1 correlated sig-
nificantly with fasting glucose (r=0.2665, p=0.0363),
insulin (r=0.4330, p=0.0004), HOMA-IR (r=0.4402,
p=0.0003), ISQUICKI (r=-0.4402, p=0.0003), HbA1c
(r=0.2724, p=0.0322), as well as with prepregnancy
and current BMI (r=0.3501, p=0.0057 and r=0.3250,
p=0.0106, respectively). In the non-pregnant women
there was only a correlation between MCP-1 and fast-
ing glucose (r=0.3580, p=0.0376). In the pregnant sub-
jects with NGT MCP-1 values were not associated
with any of the clinical or metabolic parameters stud-
ied. 
Because MCP-1 levels were most strongly associ-
ated with fasting glucose, an adjustment for this
parameter was made, and the differences in MCP-1
concentrations between the control group and the
women with NGT and GDM remained highly signifi-
cant (p<0.0001). Multiple regression analysis with
MCP-1 as a dependent value revealed that in the whole
population plasma glucose was the only significant
predictor (β=0.3489, p=0.00004), explaining about 9%
of the variance in MCP-1 concentration. In the sub-
group of pregnant women MCP-1 levels were signifi-
cantly predicted only by fasting insulin values
(β=0.2715, p=0.0323).
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Discussion
In the present study we showed that patients with
GDM were significantly more obese before pregnancy,
had higher fasting insulin levels and higher indices of
insulin resistance, whereas the subjects with NGT
demonstrated markedly lower fasting glucose and
higher insulin concentrations in comparison with the
non-pregnant group. These findings correspond to the
well known metabolic changes that occur in normal
and diabetic pregnancy. Non-diabetic pregnancy pro-
duces an "accelerated starvation" in the fasting state,
with an earlier and more profound hypoglycemia and
an increased fasting insulin level, whereas women
with GDM first of all demonstrate elevated fasting
insulin concentrations [27].
In this study we also showed that serum MCP-1
levels did not differ between women with NGT and
GDM, but were significantly lower than those
observed in the non-pregnant subjects. These findings
are in part consistent with the results obtained by Di
Benedetto et al. [24], who found similar MCP-1 serum
concentrations in women with and without a recent
history of GDM. Conversely, Denison et al. [28]
observed significantly higher release of MCP-1 from
peripheral blood cultures from pregnant women at
term as compared with non-pregnant women. The
explanation of this dicrepancy is quite a problem. In
our study MCP-1 levels were most strongly associated
with glucose concentrations, but after an adjustment
for this confounder, the difference in MCP-1 levels
between the control group and the women with NTG
and GDM remained highly significant. Moreover, in
contrast to the NGT group - demonstrating compara-
tively low fasting glucose values - glycemic levels in
GDM patients were comparable to those found in the
non-pregnant women, whereas MCP-1 concentrations
differed significantly between the two groups. These
findings suggest that factors other than glucose are
probably responsible for the observed difference in
serum MCP-1 levels between pregnant and non-preg-
nant women. One of such factors may be transforming
growth factor - beta1 (TGF-beta1) - a multifunctional
cytokine that exhibits potent immunoregulatory and
anti-inflammatory properties and prolongs graft sur-
vival [29,30]. Recent reports showed that TGF-beta1
levels were elevated in healthy pregnant women in
comparison with the non-pregnant controls and sug-
gested that TGF-beta1 may function as a regulatory
factor in fetal allograft survival during pregnancy
[29,30]. On the other hand, TGF-beta has been shown
to have immunosuppressive effects on endothelial
cells (EC). Ayatollahi et al. [31] demonstrated that EC
expressed MCP-1 mRNA and protein in response to
tumor necrosis factor-alpha (TNF alpha), interferon-
gamma (IFN-gamma) or interleukin-1beta (IL-1beta),
but not TGF-beta1. TGF-beta1 in co-treatment with
either TNF alpha or IL-1beta, significantly decreased
MCP-1 mRNA and protein expression, as compared to
TNF alpha or IL-1beta treatment alone, indicating that
TGF-beta down-modulates cytokine-induced MCP-1
expression in human EC [31]. Of course, we can only
hypothesize that TGF-beta may be a key factor respon-
sible for the alterations in circulating MCP-1 levels,
but the secretion and action of this chemokine in preg-
nant women need further investigations.
In conclusion, our results suggest that serum MCP-
1 concentrations are decreased in pregnant women,
irrespective of their glucose tolerance status.
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